Long-term prognosis after resection of cryptogenic hepatocellular carcinoma

BMC Surgery

Goro Watanabe¹  Masaji Hashimoto¹  Masamichi Matsuda¹  Kazunari Sasaki¹  Yu Ohkura¹ 

[1] Departments of Gastroenterological Surgery, Hepato Pancreato Billiary Surgery Unit, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku 105-8470, Tokyo, Japan

关键词: Long-term prognosis;    Non-B, non-C hepatocellular carcinoma;    Cryptogenic hepatocellular carcinoma;   

Others  :  1229505
DOI  :  10.1186/s12893-015-0099-9

 received in 2015-07-23, accepted in 2015-10-08,  发布年份 2015

【 摘 要 】

Background

We investigated the patterns and predictors of recurrence and survival in cryptogenic non-B, non-C, non-alcoholic hepatocellular carcinoma (CR-HCC). We compared the findings with those hepatitis virus B (B) and hepatitis virus C (C)-HCC. CR-HCC does not include HCC developed on NASH.

Methods

From 1990 to 2011, of 676 patients who underwent primary curative liver resection as initial therapy for HCC at our institution, 167 had B-HCC, 401 had C-HCC, and 62 had CR-HCC. Differences between three groups were analyzed using the Chi-squared test. Cumulative overall survival (OS) and disease-free survival (DFS) were determined by the Kaplan-Meier method, prognostic factors involved in OS/DFS were evaluated by univariate analysis using the log-rank test, and stepwise Cox regression analysis.

Results

Liver function was better in CR-HCC than in B/C-HCC, and mean tumor size was larger in CR-HCC than in B/C-HCC. In CR-HCC, OS was equivalent to that of B/C-HCC, and DFS was equivalent to that of B-HCC. Both tumor-related factors and background liver function appeared to be prognostic factors for three groups.

Conclusion

Our findings indicate that the probability of survival of advanced CR-HCC was not longer than that of B/C-HCC. Given our findings, a postoperative follow-up protocol for CR-HCC should be established alongside that for B/C-HCC.

【 授权许可】

   
2015 Ohkura et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N et al.. Nationwide study of 4741 patients with Non-B Non-C hepatocellular carcinoma with special reference to the therapeutic impact. Ann Surg. 2013; 00:1-10.
• [2]Ikai I, Arii S, Okazaki M, Okita K, OmataM KM, Takayasu K et al.. Report of the 17 th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007; 37:676-91.
• [3]The general rules for the clinical and pathological study of primary liver cancer. 3rd ed. Kanehara, Tokyo; 2010.
• [4]Hirohashi S, Blum HE, Ishak KG. Tumours of the liver and intrahepatic bile ducts. In: World Health Organisation classification of tumours: pathology and genetics of tumours of the digestive system. Hamilton SR, Aaltonen LA, editors. IARC Press, Lyon; 2000: p.157-202.
• [5]Tanaka H, Imai Y, Hiramatsu N, Hiramatsu N, Ito Y, Imanaka K et al.. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med. 2008; 148:820-6.
• [6]Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat. 2013; 2013:259148.
• [7]Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M et al.. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2014; 50(3):350-60.
• [8]Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology. 2002; 35:7-13.
• [9]Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998; 33:99-103.
• [10]Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003; 362:53-61.
• [11]Nanashima A, Abo T, Sumida Y, Takeshita H, Hidaka S, Furukawa K et al.. Clinicopathological characteristics of patients with hepatocellular carcinoma after hepatectomy: relationship with status of viral hepatitis. J Surg Oncol. 2007; 96:487-92.
• [12]Kondo K, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J. Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery. J Gastrointest Surg. 2008; 12:468-76.
• [13]Cucchetti A, Piscaqlia F, Caturelli E, Benvegnù L, Vivarelli M, Ercolani G et al.. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol. 2009; 16:413-22.
• [14]Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I et al.. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg. 2010; 34:1034-8.
• [15]Shinkawa H, Uenishi T, Takemura S, Ohba K, Ogawa M, Ichikawa T et al.. Risk factors for postoperative recurrence of non-B non-C hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2010; 17:291-5.
• [16]Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000; 232:10-24.
• [17]Wakai T, Shirai Y, Yokoyama N, Nagakura S, Hatakeyama K. Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma. Eur J Surg Oncol. 2003; 29:266-71.
• [18]Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res. 2007; 37:S95-100.
• [19]Takuma Y, Nouso K, Makino Y, Gotoh T, Toshikuni N, Morimoto Y et al.. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol. 2011; 26:1417-24.
• [20]Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma based on cryptogenic liver disease: the most common non-viral hepatocellular carcinoma in patients aged over 80 years. Hepatol Res. 2015; 45:441-7.